Nijhoff discusses the positive results of the first portion of the phase 1/2/3 trial and its implications for the underserved T1D patient population.
Michiel Nijhoff, MD
Advertisement
Dr. Nijhoff is an internist/endocrinologist at the Leiden University Medical Center in the Netherlands.
Articles by Michiel Nijhoff, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Grants Full Approval to Iptacopan (Fabhalta) in IgAN
2
Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials
3
Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD
4
COMP360 Psilocybin for TRD: What to Know Before a Possible 2027 Launch
5